Jan. 11, 2012 (China Knowledge) - State-owned Jilin Aodong Medicine Industry Group Co Ltd<000623>, one of the leading drug makers in Northeast China, reaped RMB 2.04 billion in net profit attributable to shareholders in 2011, reflecting a year-on-year increase of 65.11% from RMB 1.24 billion in 2010.

The growth was principally boosted by the company's investment return in GF Securities Co Ltd<000776>, a major brokerage firm in China, said the company.

Last year, the Shenzhen-listed firm's operating revenue reached RMB 1.15 billion, 3.17% more than RMB 1.11 billion it realized in 2010. Earnings per share were RMB 2.97, compared with nearly RMB 1.80 in 2010.

As of December 31, 2011, the drug maker had RMB 10.15 billion in total assets, whereas it had RMB 7.9 billion at the beginning of 2011, representing an increase of 26.48%.

Net asset value per share or NAVPS was RMB 13.19 at the end of 2011, 5.4% more than RMB 12.52 at the beginning of last year.

According to company's website, it had RMB 7.25 billion in net asset with debt/asset ratio of 8.26% as of December 31, 2010.